Integrated Machine Learning Approaches Highlight the Heterogeneity of Human Myeloid-Derived Suppressor Cells in Acute Sepsis

Anthony S. Bonavia; Abigail Samuelsen; E. Scott Halstead

doi:10.1101/2022.07.25.22278014

Abstract

Highly heterogeneous cell populations require multiple flow cytometric markers for appropriate phenotypic characterization. This exponentially increases the complexity of 2D scatter plot analysis and exacerbates human errors due to variations in manual gating of flow data. We describe a workflow involving the stepwise integration of several, newly available machine learning tools for the analysis of myeloid-derived suppressor cells (MDSCs) in septic and non-septic critical illness. Unsupervised clustering of flow cytometric data showed good correlation with, but significantly different numbers of, MDSCs as compared with the cell numbers obtained by manual gating. However, both quantification methods revealed a significant difference between numbers of PMN-MDSC at day 1 in healthy volunteers and critically ill patients having septic or non-septic illness. Numbers of PMN-MDSC obtained by machine learning positively correlated with 30 days hospital readmission following critical illness, whereas manual gating of this cell population distinguished between septic and non-septic critical illness. Neither gating strategy found a correlation between number of MDSCs and 30-day mortality or hospital length of stay.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding was provided by the National Institute of General Medical Sciences, grant #K08GM138825 (ASB).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All patients were enrolled at the Penn State Milton S Hershey Medical Center (Hershey, PA), following study approval by the Human Study Protection Office (Institutional Review Board Approval #15328 and #10357). Informed consent was obtained from patients having decision-making capacity, or the legally authorized healthcare representatives of patients lacking decision-making capacity.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes